AxoGen taps Karen Zaderej as CEO

AxoGen names Karen Zaderej as CEO. Release

Nuon Therapeutics taps Lee Rauch as CEO. Release

Sigma Pharmaceutical CFO Mark Smith has tendered his resignation to pursue other interests. Mark Watson a partner with KPMG will act in the role until the board has identified Smith's replacement. That process is under way. Release

Merrion Pharmaceuticals appoints Hing Kin Chan as chief business officer. Release

Infinity Pharmaceuticals names Vito Palombella chief scientific officer. Release

Germany's Noxxon Pharma appoints Aram Mangasarian as chief business officer. Release

Emmanuel le Poul, head of the CNS business unit at Addex Pharmaceuticals, will be leaving the company to pursue other opportunities. Addex does not intend to replace him in the short term. Release

Sigma-Aldrich has announced the retirement of David Julien, president global supply chain, effective June 30. Joseph Porwoll has been promoted to vice president, global supply chain and will take over the responsibilities held by Julien. Release

Xenon Pharmaceuticals has appointed Tarek Mansour as executive VP of R&D. Release

Pekka Kaivola, senior VP responsible for the global sales line function of the Orion Group and member of the executive management board, will retire Dec. 31. He will leave his present position Oct. 1, continuing as senior advisor until his retirement. Satu Ahomäki, currently senior VP responsible for Orion's animal health business division,  has been appointed senior VP responsible for the global sales line function, as of Oct. 1.  A new head will be appointed for the animal health business. Release

Oxygen Biotherapeutics has hired Jim Weiss to the newly created position of sales director. Release

Immunovaccine appoints Paul Kirkconnell to board. Release

Former Pfizer CEO Henry McKinnell, Jr., is joining Emmaus Medical's board of directors. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.